Adalimumab in the treatment of pediatric Behçet’s disease

case-based review

Dimitri Poddighe, Zaure Mukusheva, Kaisar Dauyey, Maikesh Assylbekova

Research output: Contribution to journalArticle

Abstract

Behçet’s disease (BD) is a systemic vasculitis affecting prominently the veins, which is usually diagnosed in adulthood, but can occur in children younger than 16 years in about 4–26% of cases. The therapy is based on several immune-suppressive drugs; in case of inadequate control and/or complications, the biologic therapy with anti-TNF drugs has been successfully used in adults. Here, we reported one pediatric case of BD with systemic (persistent/recurrent high fever), skin and mucosal manifestations (recurrent aphthous stomatitis, anal/penile ulcers, erythema nodosum and papulo-pustules), that were unresponsive to the conventional treatment with steroids and colchicine; however, he was successfully treated with adalimumab. Compared to adult patients, the experience with adalimumab in the treatment of pediatric BD is very limited. Indeed, through a systematic search in the medical literature, we retrieved 4 case reports and 2 case series, describing BD pediatric patients treated with adalimumab, in addition to three clinical studies including some BD children. The analysis and discussion of these available clinical experiences may indicate adalimumab as an effective and safe option to treat several forms of BD, in addition to BD-related chronic uveitis.

Original languageEnglish
Pages (from-to)1107-1112
Number of pages6
JournalRheumatology International
Volume39
Issue number6
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

Pediatrics
Therapeutics
Fissure in Ano
Skin Manifestations
Erythema Nodosum
Systemic Vasculitis
Biological Therapy
Uveitis
Colchicine
Adalimumab
Pharmaceutical Preparations
Veins
Fever
Steroids

Keywords

  • Adalimumab
  • Behçet’s disease
  • Pediatric rheumatology

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Adalimumab in the treatment of pediatric Behçet’s disease : case-based review. / Poddighe, Dimitri; Mukusheva, Zaure; Dauyey, Kaisar; Assylbekova, Maikesh.

In: Rheumatology International, Vol. 39, No. 6, 01.06.2019, p. 1107-1112.

Research output: Contribution to journalArticle

Poddighe, Dimitri ; Mukusheva, Zaure ; Dauyey, Kaisar ; Assylbekova, Maikesh. / Adalimumab in the treatment of pediatric Behçet’s disease : case-based review. In: Rheumatology International. 2019 ; Vol. 39, No. 6. pp. 1107-1112.
@article{a5997e3482e4403fbcf3cf6763e5eab8,
title = "Adalimumab in the treatment of pediatric Beh{\cc}et’s disease: case-based review",
abstract = "Beh{\cc}et’s disease (BD) is a systemic vasculitis affecting prominently the veins, which is usually diagnosed in adulthood, but can occur in children younger than 16 years in about 4–26{\%} of cases. The therapy is based on several immune-suppressive drugs; in case of inadequate control and/or complications, the biologic therapy with anti-TNF drugs has been successfully used in adults. Here, we reported one pediatric case of BD with systemic (persistent/recurrent high fever), skin and mucosal manifestations (recurrent aphthous stomatitis, anal/penile ulcers, erythema nodosum and papulo-pustules), that were unresponsive to the conventional treatment with steroids and colchicine; however, he was successfully treated with adalimumab. Compared to adult patients, the experience with adalimumab in the treatment of pediatric BD is very limited. Indeed, through a systematic search in the medical literature, we retrieved 4 case reports and 2 case series, describing BD pediatric patients treated with adalimumab, in addition to three clinical studies including some BD children. The analysis and discussion of these available clinical experiences may indicate adalimumab as an effective and safe option to treat several forms of BD, in addition to BD-related chronic uveitis.",
keywords = "Adalimumab, Beh{\cc}et’s disease, Pediatric rheumatology",
author = "Dimitri Poddighe and Zaure Mukusheva and Kaisar Dauyey and Maikesh Assylbekova",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s00296-019-04300-0",
language = "English",
volume = "39",
pages = "1107--1112",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Adalimumab in the treatment of pediatric Behçet’s disease

T2 - case-based review

AU - Poddighe, Dimitri

AU - Mukusheva, Zaure

AU - Dauyey, Kaisar

AU - Assylbekova, Maikesh

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Behçet’s disease (BD) is a systemic vasculitis affecting prominently the veins, which is usually diagnosed in adulthood, but can occur in children younger than 16 years in about 4–26% of cases. The therapy is based on several immune-suppressive drugs; in case of inadequate control and/or complications, the biologic therapy with anti-TNF drugs has been successfully used in adults. Here, we reported one pediatric case of BD with systemic (persistent/recurrent high fever), skin and mucosal manifestations (recurrent aphthous stomatitis, anal/penile ulcers, erythema nodosum and papulo-pustules), that were unresponsive to the conventional treatment with steroids and colchicine; however, he was successfully treated with adalimumab. Compared to adult patients, the experience with adalimumab in the treatment of pediatric BD is very limited. Indeed, through a systematic search in the medical literature, we retrieved 4 case reports and 2 case series, describing BD pediatric patients treated with adalimumab, in addition to three clinical studies including some BD children. The analysis and discussion of these available clinical experiences may indicate adalimumab as an effective and safe option to treat several forms of BD, in addition to BD-related chronic uveitis.

AB - Behçet’s disease (BD) is a systemic vasculitis affecting prominently the veins, which is usually diagnosed in adulthood, but can occur in children younger than 16 years in about 4–26% of cases. The therapy is based on several immune-suppressive drugs; in case of inadequate control and/or complications, the biologic therapy with anti-TNF drugs has been successfully used in adults. Here, we reported one pediatric case of BD with systemic (persistent/recurrent high fever), skin and mucosal manifestations (recurrent aphthous stomatitis, anal/penile ulcers, erythema nodosum and papulo-pustules), that were unresponsive to the conventional treatment with steroids and colchicine; however, he was successfully treated with adalimumab. Compared to adult patients, the experience with adalimumab in the treatment of pediatric BD is very limited. Indeed, through a systematic search in the medical literature, we retrieved 4 case reports and 2 case series, describing BD pediatric patients treated with adalimumab, in addition to three clinical studies including some BD children. The analysis and discussion of these available clinical experiences may indicate adalimumab as an effective and safe option to treat several forms of BD, in addition to BD-related chronic uveitis.

KW - Adalimumab

KW - Behçet’s disease

KW - Pediatric rheumatology

UR - http://www.scopus.com/inward/record.url?scp=85065461500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065461500&partnerID=8YFLogxK

U2 - 10.1007/s00296-019-04300-0

DO - 10.1007/s00296-019-04300-0

M3 - Article

VL - 39

SP - 1107

EP - 1112

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 6

ER -